Clinical Trial Update: Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating alemtuzumab with combination chemotherapy followed by donor lymphocyte infusion in patients undergoing donor stem cell transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Disorders

Drugs mentioned

• Alemtuzumab (Campath) (alemtuzumab)

Snippet

Sponsor: Yale University | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Status: COMPLETED